Boehringer Ingelheim Launches LENZELTA® Vaccine to Enhance Mastitis Prevention in Dairy Cows

• LENZELTA^® is a novel vaccine that markedly lowers the rate and seriousness of clinical mastitis in immunized cows and heifers¹. It is administered simply via two doses during the dry-off phase.
• Mastitis remains a critical issue globally for dairy producers and veterinarians, affecting bovine health and creating significant financial strain on farming operations.
• Among bovine mastitis vaccines, LENZELTA^® provides the quickest start to immunity and the most enduring protection against the primary pathogens S. aureus and E. coli².

(SeaPRwire) –   By introducing LENZELTA^®, Boehringer Ingelheim expands its extensive mastitis range, providing producers and vets with efficient tools to maintain cattle health and farm sustainability. Availability in select European Union nations begins in April 2026.

Mastitis is one of the most common and financially damaging diseases affecting dairy cattle. It compromises udder health and diminishes milk yield and quality, resulting in major production losses. On numerous dairy farms, expenses related to mastitis constitute one of the largest preventable economic drains on the herd³. Since cows are highly susceptible around the time of calving, preventive measures during the dry-off period are essential for preserving herd welfare and facilitating a seamless transition into lactation.

A novel preventive instrument for veterinarians and producers

LENZELTA^® addresses the two major mastitis-causing pathogens, S. aureus and E. coli, assisting farmers and veterinarians in proactively managing infections. By prioritizing prevention at a pivotal point in the lactation cycle, the vaccine fosters a more stable environment for milk yield and animal welfare.

Given in two doses during the dry-off interval, LENZELTA^® integrates smoothly into existing herd health protocols. This schedule ensures immunity develops quickly and offers protection for up to six months, spanning the timeframe when cows are most prone to mastitis⁴. The vaccine utilizes an oil-free adjuvant and comes in various vial sizes, providing veterinarians with practical flexibility in their daily work.

For veterinarians, LENZELTA^® presents a pragmatic method for proactive mastitis management. It bolsters a preventive strategy and facilitates more sustainable care for dairy herds.

For farmers, LENZELTA^® can restore a sense of control, assurance, and peace of mind by lowering the occurrence and effects of mastitis infections. The vaccine promotes healthier cattle, aids in boosting herd productivity, and contributes to more dependable milk output and farm management.

“LENZELTA^® establishes a new standard in mastitis prevention,” states Dr. Gerald Behrens, Head of Ruminants at Boehringer Ingelheim. “Mastitis imposes a heavy burden on dairy farms globally. By providing a highly effective vaccine that fits easily into current practices, we equip farmers and veterinarians with a potent new instrument to handle one of the industry’s most enduring difficulties.”

Beginning in April, LENZELTA^® will be released in various countries throughout the EU.

References

¹ Lenzelta, Suspension for injection | UPD

² noahcompendium.co.uk/?id=-452828

³ Stanek P., Żółkiewski P., Januś E. A review on mastitis in dairy cows research: Current status and future perspectives. Agriculture. 2024; 14(8):1292.
https://doi.org/10.3390/agriculture14081292

⁴ Puerto M.A., Shepley E., Cue R.I., Warner D., Dubuc J., Vasseur E. The hidden cost of disease: Impact of the first incidence of mastitis on production and economic indicators of primiparous dairy cows. Journal of Dairy Science, Volume 104, Issue 7, 7932 – 7943
https://doi.org/10.3168/jds.2020-19584

Boehringer Ingelheim – Animal Health business

Boehringer Ingelheim delivers innovative solutions for the prevention and treatment of animal diseases. The company supplies a broad portfolio of vaccines, parasite-control products, and medications for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. Recognizing the deep connection between human and animal health as a leader in the industry, Boehringer Ingelheim strives to make a positive impact for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim

Boehringer Ingelheim operates as a biopharmaceutical entity engaged in both human and animal health sectors. As one of the industry’s leading investors in Research and Development, the company concentrates on creating innovative therapies for areas with significant unmet medical needs. Independent since its establishment in 1885, Boehringer adopts a long-term view, integrating sustainability throughout the entire value chain. With over 53,500 employees serving more than 130 markets, the company aims to build a healthier, more sustainable, and equitable future. Learn more at www.boehringer-ingelheim.com.

Intended Audiences Notice

This press release originates from our Corporate Headquarters in Ingelheim, Germany and is intended to convey information regarding our global business. Please note that details concerning product approval status and labels may differ by country, and a country-specific press release on this subject may have been distributed in the regions where we operate.